Eli Lilly (LLY) valuation
Eli Lilly P/E ratio history
Eli Lilly trades at 46.0 times its earnings over the last twelve months and 31.0 times the earnings analysts expect over the next twelve. At its last 9 fiscal year ends its P/E ranged from 15.0 (year to Dec 2019) to 100.5 (year to Dec 2023), with a median of 45.1.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $1,075 | $22.95 | 46.8 | 35.5 |
| Dec 31, 2024 | $772.00 | $11.71 | 65.9 | 38.1 |
| Dec 31, 2023 | $582.92 | $5.80 | 100.5 | 53.2 |
| Dec 31, 2022 | $365.84 | $6.90 | 53.0 | 41.6 |
| Dec 31, 2021 | $276.22 | $6.12 | 45.1 | 37.1 |
| Dec 31, 2020 | $168.84 | $6.79 | 24.9 | — |
| Dec 31, 2019 | $131.43 | $8.76 | 15.0 | — |
| Dec 31, 2018 | $115.72 | $3.13 | 37.0 | — |
| Dec 31, 2017 | $84.46 | -$0.20 | n/m | — |
| Dec 31, 2016 | $73.55 | $2.58 | 28.5 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Eli Lilly valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Eli LillyLLY | $1.33T | 46.0 | 31.0 | 15.4 |
| Johnson & JohnsonJNJ | $658B | 41.5 | 23.8 | 6.6 |
| MerckMRK | $369B | 119.6 | 25.0 | 5.6 |
| Novo NordiskNVO | $178B | 9.9 | — | 3.5 |
| PfizerPFE | $174B | 40.2 | 10.5 | 2.7 |
| Bristol Myers SquibbBMY | $128B | 13.8 | 9.5 | 2.6 |
| ZoetisZTS | $33.4B | 13.0 | 12.6 | 3.5 |
| ViatrisVTRS | $22.2B | — | 7.3 | 1.5 |
| Corcept TherapeuticsCORT | $8.71B | 193.1 | 25.7 | 10.5 |
| Peer median | 40.2 | 12.6 | 3.5 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: LLY financials · LLY returns
No forecast, no recommendation. This page describes Eli Lilly from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.